Rhenman & Partners Asset Management AB Has $2.98 Million Stock Position in Arvinas, Inc. (NASDAQ:ARVN)

Rhenman & Partners Asset Management AB increased its position in shares of Arvinas, Inc. (NASDAQ:ARVN) by 19.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,500 shares of the company’s stock after acquiring an additional 25,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Arvinas were worth $2,981,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. KBC Group NV grew its position in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after purchasing an additional 1,255 shares in the last quarter. Quantbot Technologies LP lifted its holdings in shares of Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Arvinas in the fourth quarter worth $171,000. Teacher Retirement System of Texas grew its holdings in shares of Arvinas by 19.0% during the fourth quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company’s stock valued at $274,000 after buying an additional 2,280 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Arvinas by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock valued at $279,000 after buying an additional 1,367 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ARVN shares. Wedbush downgraded Arvinas from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $57.00 to $12.00 in a research note on Wednesday, March 12th. BMO Capital Markets set a $20.00 price target on shares of Arvinas and gave the stock an “outperform” rating in a research report on Wednesday, March 12th. Wells Fargo & Company set a $26.00 price objective on shares of Arvinas and gave the company an “overweight” rating in a research report on Wednesday, March 12th. Morgan Stanley cut their target price on shares of Arvinas from $48.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, March 13th. Finally, Citigroup decreased their target price on shares of Arvinas from $28.00 to $19.00 and set a “neutral” rating for the company in a research note on Friday, March 7th. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, Arvinas currently has a consensus rating of “Moderate Buy” and an average price target of $35.50.

Arvinas Price Performance

Shares of NASDAQ:ARVN opened at $6.56 on Friday. The stock has a market capitalization of $451.14 million, a P/E ratio of -2.37 and a beta of 2.30. The business has a 50-day moving average of $14.15 and a two-hundred day moving average of $20.07. Arvinas, Inc. has a fifty-two week low of $6.24 and a fifty-two week high of $39.34.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period last year, the company posted ($2.53) earnings per share. As a group, research analysts expect that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insider Transactions at Arvinas

In related news, insider Noah Berkowitz sold 8,658 shares of Arvinas stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the transaction, the insider now owns 110,023 shares in the company, valued at $945,097.57. This trade represents a 7.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John G. Houston sold 31,338 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,230 shares of company stock worth $769,402. 5.23% of the stock is owned by insiders.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.